Virus-based bladder treatment for BCG-unresponsive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is for people with bladder cancer that has not responded to BCG therapy. The study tests a new virus-based treatment (called cretostimogene grenadenorepvec) that is given directly into the bladder to help fight the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bladder cancer that is in the inner lining of the bladder (called carcinoma in situ, or CIS) and it did not go away or came back after BCG treatment.
- You have had at least one full course of BCG (typically 6 weekly treatments plus at least 2 more) within the last 15 months.
- All visible tumors have been removed or destroyed before starting the study treatment.
- You are not able to have your bladder removed (radical cystectomy) for medical reasons, or you have chosen not to have that surgery.
- Your cancer has not spread into the muscle layer of the bladder or beyond.
- You have not had other cancer treatments (like chemotherapy) within the last 4 weeks, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, Cretostimogene, for people with a type of bladder cancer that hasn't spread into the muscle layer (non-muscle invasive) and has not responded to standard BCG treatment. The goal is to see if this drug can help control the cancer and avoid the need for bladder removal surgery.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This trial tests radiotherapy (high-energy X-rays) for a specific type of early-stage bladder cancer (CIS) that hasn't gone away after BCG treatment. It's for people who can't or choose not to have bladder removal surgery.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.